Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBX7455 for Hepatic Encephalopathy in Cirrhosis
NCT04155099Phase 2Terminated
- Sponsor
- Ochsner Clinic Foundation
- Start
- Mar 2021
- Primary completion
- Jul 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of RBX7455 in hepatic encephalopathy (HE), sponsored by Ochsner Clinic Foundation. Started Mar 2021; status: terminated.
02
Drugs
RBX7455
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT04155099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04155099.